{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:23:14Z","timestamp":1793467394625,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Neurosciences"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.tins.2009.06.002","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T04:14:02Z","timestamp":1253592842000},"page":"591-601","source":"Crossref","is-referenced-by-count":587,"title":["Multiple roles of HDAC inhibition in neurodegenerative conditions"],"prefix":"10.1016","volume":"32","author":[{"given":"De-Maw","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tso","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tins.2009.06.002_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/med.20024","article-title":"Histone deacetylation in epigenetics: an attractive target for anticancer therapy","volume":"25","author":"Mai","year":"2005","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.tins.2009.06.002_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1568007053005091","article-title":"Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents","volume":"4","author":"Langley","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.tins.2009.06.002_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coph.2007.12.002","article-title":"Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders","volume":"8","author":"Abel","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tins.2009.06.002_bib4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","article-title":"Therapeutic application of histone deacetylase inhibitors for central nervous system disorders","volume":"7","author":"Kazantsev","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tins.2009.06.002_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00439-005-1331-y","article-title":"DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein\u2013Taybi syndrome (RSTS) and in another patient with incomplete RSTS","volume":"117","author":"Bartsch","year":"2005","journal-title":"Hum. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/138161208783885335","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"14","author":"Itoh","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tins.2009.06.002_bib7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.tins.2009.06.002_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.coph.2006.03.010","article-title":"Histone deacetylase inhibitors: gathering pace","volume":"6","author":"Carey","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tins.2009.06.002_bib9","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1091\/mbc.E05-01-0033","article-title":"Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins","volume":"16","author":"Michishita","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.tins.2009.06.002_bib10","first-page":"589","article-title":"Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene","volume":"16","author":"Voelter-Mahlknecht","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.tins.2009.06.002_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.tins.2009.06.002_bib12","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tins.2009.06.002_bib13","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.tins.2009.06.002_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.tins.2009.06.002_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","article-title":"Histone deacetylase inhibitors as therapeutics for polyglutamine disorders","volume":"7","author":"Butler","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.tins.2009.06.002_bib17","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2009.06.002_bib18","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/jm049002a","article-title":"Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides","volume":"48","author":"Mai","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tins.2009.06.002_bib19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cmdc.200700003","article-title":"Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins)","volume":"2","author":"Trapp","year":"2007","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.tins.2009.06.002_bib20","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1523\/JNEUROSCI.3203-08.2008","article-title":"Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau","volume":"28","author":"Green","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib21","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1093\/emboj\/cdg615","article-title":"Critical loss of CBP\/p300 histone acetylase activity by caspase-6 during neurodegeneration","volume":"22","author":"Rouaux","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.tins.2009.06.002_bib22","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1073\/pnas.0737363100","article-title":"Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway","volume":"100","author":"Ryu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2009.06.002_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0014-5793(03)00350-8","article-title":"Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition","volume":"542","author":"Jeong","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tins.2009.06.002_bib24","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.1523\/JNEUROSCI.1570-05.2005","article-title":"Bim is a direct target of a neuronal E2F-dependent apoptotic pathway","volume":"25","author":"Biswas","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1523\/JNEUROSCI.3200-07.2008","article-title":"Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1\/cip1) in cell cycle-independent neuroprotection","volume":"28","author":"Langley","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib26","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1523\/JNEUROSCI.6186-08.2009","article-title":"Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms","volume":"29","author":"Uo","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cnr.2004.09.016","article-title":"Lithium protection from glutamate excitotoxicity: therapeutic implications","volume":"4","author":"Chuang","year":"2004","journal-title":"Clin. Neurosci. Res."},{"key":"10.1016\/j.tins.2009.06.002_bib28","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1523\/JNEUROSCI.0096-06.2006","article-title":"Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity","volume":"26","author":"Leng","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.tpj.6500269","article-title":"Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons","volume":"4","author":"Kanai","year":"2004","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.tins.2009.06.002_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.45.120403.095902","article-title":"Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases","volume":"45","author":"Chuang","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tins.2009.06.002_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ncb1747","article-title":"Nitric oxide-induced nuclear GAPDH activates p300\/CBP and mediates apoptosis","volume":"10","author":"Sen","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tins.2009.06.002_bib32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1471-4159.2007.04778.x","article-title":"Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death","volume":"103","author":"Monti","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2009.06.002_bib33","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib34","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1523\/JNEUROSCI.5467-07.2008","article-title":"Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition","volume":"28","author":"Leng","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.mp.4002099","article-title":"The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons","volume":"14","author":"Yasuda","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tins.2009.06.002_bib36","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/sj.mp.4001893","article-title":"Valproate protects dopaminergic neurons in midbrain neuron\/glia cultures by stimulating the release of neurotrophic factors from astrocytes","volume":"11","author":"Chen","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tins.2009.06.002_bib37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1017\/S1461145708009024","article-title":"Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons","volume":"11","author":"Wu","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tins.2009.06.002_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molbrainres.2004.10.021","article-title":"Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia","volume":"134","author":"Peng","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.tins.2009.06.002_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2007.06.053","article-title":"Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity","volume":"149","author":"Chen","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.tins.2009.06.002_bib40","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/sj.bjp.0705682","article-title":"Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids","volume":"141","author":"Huuskonen","year":"2004","journal-title":"Br J. Pharmacol."},{"key":"10.1016\/j.tins.2009.06.002_bib41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1471-4159.2004.02406.x","article-title":"Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction","volume":"89","author":"Ren","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2009.06.002_bib42","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/jpet.107.120188","article-title":"Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action","volume":"321","author":"Kim","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tins.2009.06.002_bib43","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1124\/mol.106.027912","article-title":"Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain","volume":"70","author":"Faraco","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tins.2009.06.002_bib44","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1471-4159.2009.06212.x","article-title":"The histone deacetylase inhibitor, sodium butyrate, stimulates cell proliferation in the ischemic brain: roles of BDNF-TrkB signaling","volume":"110","author":"Kim","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2009.06.002_bib45","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1124\/mol.104.001339","article-title":"Sodium 4-phenylbutyrate protects against cerebral ischemic injury","volume":"66","author":"Qi","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tins.2009.06.002_bib46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.jcbfm.9600502","article-title":"Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke","volume":"28","author":"Zheng","year":"2008","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.tins.2009.06.002_bib47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1471-4159.2006.04016.x","article-title":"Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen\/glucose deprivation","volume":"98","author":"Meisel","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2009.06.002_bib48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.expneurol.2007.11.031","article-title":"Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury","volume":"210","author":"Yildirim","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tins.2009.06.002_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.nbd.2007.02.006","article-title":"Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation","volume":"26","author":"Sinn","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2009.06.002_bib50","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1096\/fj.08-108548","article-title":"Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice","volume":"22","author":"Granger","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.tins.2009.06.002_bib51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington's disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/13543784.17.2.169","article-title":"Histone deacetylase inhibitors: possible implications for neurodegenerative disorders","volume":"17","author":"Hahnen","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tins.2009.06.002_bib54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tins.2009.06.002_bib55","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1523\/JNEUROSCI.3344-05.2006","article-title":"Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity","volume":"26","author":"Bates","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib56","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.tins.2009.06.002_bib58","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2009.06.002_bib59","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib60","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib61","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2009.06.002_bib62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tins.2009.06.002_bib63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.tins.2009.06.002_bib64","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/hmg\/ddh144","article-title":"Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach","volume":"13","author":"Hay","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib65","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1523\/JNEUROSCI.4522-06.2007","article-title":"The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes","volume":"27","author":"Tagawa","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib66","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","article-title":"Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation","volume":"27","author":"Dompierre","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib67","doi-asserted-by":"crossref","first-page":"40282","DOI":"10.1074\/jbc.M508786200","article-title":"HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin","volume":"280","author":"Iwata","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tins.2009.06.002_bib68","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nature05853","article-title":"HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS","volume":"447","author":"Pandey","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.tins.2009.06.002_bib69","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice","volume":"93","author":"Ryu","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2009.06.002_bib70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17482960802226148","article-title":"Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice","volume":"10","author":"Del Signore","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.tins.2009.06.002_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nbd.2005.09.013","article-title":"Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"22","author":"Petri","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2009.06.002_bib72","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1523\/JNEUROSCI.1470-07.2007","article-title":"Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS","volume":"27","author":"Ferraiuolo","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib73","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1111\/j.1460-9568.2004.03765.x","article-title":"Benefit of valproic acid in suppressing disease progression of ALS model mice","volume":"20","author":"Sugai","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib74","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.1139-07.2007","article-title":"Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Rouaux","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib75","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuroscience.2008.06.040","article-title":"Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"155","author":"Feng","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.tins.2009.06.002_bib76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17482960802320487","article-title":"Phase 2 study of sodium phenylbutyrate in ALS","volume":"10","author":"Cudkowicz","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.tins.2009.06.002_bib77","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2009.06.002_bib78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib79","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2009.06.002_bib80","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tins.2009.06.002_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Hum. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib83","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib84","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tins.2009.06.002_bib85","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib86","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.nbd.2006.07.004","article-title":"Establishing a standardized therapeutic testing protocol for spinal muscular atrophy","volume":"24","author":"Tsai","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2009.06.002_bib87","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00109-008-0388-1","article-title":"Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice","volume":"86","author":"Tsai","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.tins.2009.06.002_bib88","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.nbd.2008.05.014","article-title":"Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy","volume":"31","author":"Tsai","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2009.06.002_bib89","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","author":"Mercuri","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.tins.2009.06.002_bib90","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.tins.2009.06.002_bib91","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2009.06.002_bib92","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.tins.2009.06.002_bib93","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","article-title":"Valproic acid treatment in six patients with spinal muscular atrophy","volume":"14","author":"Tsai","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tins.2009.06.002_bib94","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1385\/NMM:5:3:235","article-title":"Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity","volume":"5","author":"Gardian","year":"2004","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.tins.2009.06.002_bib95","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tins.2009.06.002_bib96","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.1143780","article-title":"Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease","volume":"317","author":"Outeiro","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.tins.2009.06.002_bib97","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1021\/bi035627j","article-title":"Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing","volume":"43","author":"Su","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.tins.2009.06.002_bib98","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nature05772","article-title":"Recovery of learning and memory is associated with chromatin remodelling","volume":"447","author":"Fischer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.tins.2009.06.002_bib99","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuron.2008.10.015","article-title":"Deregulation of HDAC1 by p25\/Cdk5 in neurotoxicity","volume":"60","author":"Kim","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.tins.2009.06.002_bib100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature07925","article-title":"HDAC2 negatively regulates memory formation and synaptic plasticity","volume":"459","author":"Guan","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tins.2009.06.002_bib101","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1101\/lm.917508","article-title":"Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory","volume":"15","author":"Barrett","year":"2008","journal-title":"Learn. Mem."},{"key":"10.1016\/j.tins.2009.06.002_bib102","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/npp.2008.229","article-title":"Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model","volume":"34","author":"Ricobaraza","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tins.2009.06.002_bib103","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models","volume":"205","author":"Qing","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tins.2009.06.002_bib104","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","article-title":"SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis","volume":"26","author":"Kim","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.tins.2009.06.002_bib105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/138920107783018417","article-title":"Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell","volume":"8","author":"Bruserud","year":"2007","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["Trends in Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166223609001337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166223609001337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:24:04Z","timestamp":1558538644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166223609001337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0166223609001337"],"URL":"https:\/\/doi.org\/10.1016\/j.tins.2009.06.002","relation":{},"ISSN":["0166-2236"],"issn-type":[{"value":"0166-2236","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}